RecruitingPhase 4NCT06642272
A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
Sponsor
Herlev and Gentofte Hospital
Enrollment
17,200 participants
Start Date
Oct 10, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of this clinical trial is investigate the comparative effectiveness of empagliflozin and dapagliflozin for the treatment of diabetes, chronic kidney disease, and heart failure. Patients who are prescribed either empagliflozin or dapagliflozin, as part of daily clinical practice at the participating sites, will be included in the study. Treatment will be randomized automatically through the electronic health record software in clusters defined by time of day. https://www.appletreestudy.com
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Adults aged 18 years or more
Exclusion Criteria2
- Incapabability of giving informed consent
- Withdrawal of informed consent
Interventions
DRUGEmpagliflozin 10 MG
Once daily
DRUGDapagliflozin 10 MG
Once daily
Locations(12)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06642272
Related Trials
Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
NCT0659339212 locations
Mind Your Heart-II
NCT054311921 location
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370641 locations
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418115 locations
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT070644731153 locations